ABSTRACT'. IGF-I, IGF-11, and their binding proteins (BP) were studied in sera obtained by direct puncture of umbilical cords in utero between 20 and 37 wk of gestation in 103 normal fetuses and in 16 fetuses with intrauterine growth retardation, as well as in the cord blood of 37 normal newborns of 38-to 42-wk pregnancies. In normal fetuses, IGF-I levels were approximately 50 ng/mL and IGF-I1 levels approximately 350 ng/mL up to the 33rd wk of pregnancy. Thereafter, both increased to reach values two to three times higher at term. Correlations were found between fetal placental lactogen levels and those of IGF-I and IGF-11, which is consistent with the hypothesis that placental lactogen is involved in the regulation of IGF synthesis in the fetus. With weight (either measured at birth or deduced from echographical data) as index of fetal size, IGF-I levels were significantly ( p < 0.001) higher in fetuses with weights above the mean for gestational age than in fetuses with weights below the mean, whereas IGF-I1 levels were similar in the two groups. Similarly, IGF-I (but not IGF-11) levels in fetuses with intrauterine growth retardation were significantly lower than those in normal fetuses of the same age ( p < 0.01). These findings suggest that, during the latter months of intrauterine life, IGF-I (but not IGF-11) is involved in the control of fetal size. Total fetal BP concentrations were approximately '/J those of adults. The fetal electrophoretic profile obtained by Western-ligand blotting bore a strong resemblance to that of subjects with growth hormone deficiency. In newborns, the proportions of IGF-I and IGF-I1 associated with BP to form 150-kD complexes were considerably lower than those in adults, but similar to those in hypopituitary patients. It may be deduced from these findings that during fetal life, BP synthesis is adapted to increase the bioavailability of the IGF at a time when growth is at a maximum.
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The involvement of IGF in fetal growth has long been suspected and, in view of the developmental switch from IGF-I1 to IGF-I in the rat (I, 2), it has been suggested that IGF-I1 could be the fetal somatomedin (reviews in 3 and 4). In man, correlations have been seen between body weight or length at birth, somatomedin activity, and IGF levels in cord blood (5) (6) (7) (8) . Furthermore, IGF-specific receptors have been found in a wide variety of tissues (9-1 1). More recently, mitogenic effects of IGF on several types of human fetal cells have been demonstrated (12) (13) (14) . The ubiquitous production of IGF, initially suggested by their presence in extracts of a wide variety of organs and tissues (1 5), has been confirmed by immunocytochemistry (1 6) and detection of their mRNA (1 7, 18). Consequently, greater emphasis has been placed on the paracrine action of IGF (19) and doubt thrown on the significance of their circulating levels. However, although IGF mRNA have been found in virtually all human fetal tissues, they are most abundant in fetal liver, where IGF-I1 expression is much higher than IGF-I expression (18) . It can therefore be postulated that circulating IGF levels reflect IGF production in the liver, as has been shown in the rat (20) , and that IGF have an endocrine action.
The bioavailability of the IGF is in large part determined by the relative proportions of specific BP (review in 21), of which we have identified five molecular forms in man, each differing in its regulation and its afinities for IGF-I and IGF-I1 (22, 23).
The purpose of our study was to measure serum IGF and BP levels in the course of the development of the human fetus and to analyze their relationships with fetal size in normal subjects and in cases of IUGR.
Abbreviations

MATERIALS AND METHODS
BP (or IGF-BP), IGF binding protein
Serum samples. Fetal serum samples were obtained by direct IUGR, intrauterine growth retardation puncture of the umbilical cord in utero as previously described PL, placental lactogen (24) . 1) Between 20 and 37 wk of pregnancy, 103 samples were taken for prenatal diagnosis of mother-to-fetus transmissible intolerance. The results of assays done on these samples were therefore considered as normal reference values. 2) Sixteen severely growth-retarded fetuses were sampled for a variety of investigations, in particular karyotype determination. In none of the cases selected for this study were any disorders detected that might account for the IUGR.
Cord blood was collected from 37 normal newborns (38 to 42 wk of pregnancy). Fetal age was expressed in wk from the 1st d of the last menstrual period.
Comparisons were made with individual or pooled samples of normal adult serum (mean age of the subjects, 28 y) as well as with samples from 18 untreated subjects suffering from idiopathic GH deficiency (GH level below 5 ng/mL in two stimulation tests).
Indices ofgrowth. Weight was c'~osen as the index of fetal size.
Estimations of fetal weight were based on echographical data, according to Warsof et a/. (25) . Fetuses were classified as "large"
or "small" on the basis of their weight being above or below the 50th percentile for fetuses of the same age. Newborns were classified in the same way using the 50th percentile of the weightto-gestational-age curve established by Leroy and Lefort (26) . In the 16 cases of IUGR, diagnosis was confirmed by measurement of birth weight that was below the 3rd percentile. IGF-I, IGF-11, and binding activity measurements. These assays have been described in detail previously (27, 28) . Samples were gel filtered on 1.5 x 30 cm columns of Ultrogel AcA 54 (IBF, Villeneuve-La-Garenne, France) in 1 M CH3COOH, 0.15 M NaCI, 0.1% BSA. BP were collected in the material eluting between 47 and 66% of the bed volume and IGF in that eluting between 77 and 90%. The eluates were lyophilized and then desalted on Sephadex G 25 disposable columns (Pharmacia, Uppsala, Sweden) in the assay buffer. Pure IGF-I (preparation 1 :4) and IGF-I1 (preparation 9 SE IV) purified from human serum were generously provided by Dr. R.
E. Humbel (Zurich, Switzerland) and were used as standards and as tracer after iodination by the chloramine T method. IGF-I was assayed by RIA using the anti-IGF-I antiserum prepared by Drs. L. Underwood and J. J. Van Wyk (Chapel Hill, NC) and kindly provided by the Hormone Distribution Program, NIDDK, University of Maryland School of Medicine. IGF-I1 was measured by competitive protein binding assay using BP extracted from human cerebrospinal fluid, which have a selective affinity for IGF-11. IGF-I and IGF-I1 were assayed simultaneously. Unknown samples were studied at three concentrations, each in duplicate, plus one blank (tube without antibody or BP).
For the binding activity measurements, the relative BP concentration in each sample was assessed in terms of its binding to '251-IGF-I compared with a reference BP preparation extracted from a pool of normal serum and arbitrarily assigned a value of 1 U BP/mL. Samples were studied at six concentrations, each in duplicate.
Incubations were done at 4°C in 0.1 M sodium phosphate buffer, pH 7.5, 0.2% BSA (total volume, 0.4 mL) for 3 d in the case of the IGF-I RIA and for 18-24 h in the case of the IGF-I1 and binding activity assays. Free and bound IGF were separated using albumin-coated charcoal.
For the IGF-I and IGF-I1 assays, the intraassay coefficient of variation was 4% and the interassay coefficient (including the gel filtration step) was 15%. For binding activity, these values were 6 and 18%, respectively.
Preparation of the 150-kD and 40-kD IGF-BP complexes. The technique has been described in detail elsewhere (29) . Briefly, serum samples were gel filtered on 1.6 x 40 cm columns of Ultrogel AcA 44 in 0.02 M Tris-HCI, pH 7.4, 0.15 M NaC1, 0.1 % BSA, 0.05% NaN3. The 150-kD complexes were collected in the material eluting between 4 and 15% of the bed volume and the 40-kD complexes in that eluting between 24 and 46%. The eluates were lyophilized and then submitted to acidic gel filtration for IGF-I and IGF-I1 measurement.
Western-ligand blotting. The method has been described in detail elsewhere (30) . Samples (3 or 6 pL serum) were diluted in 0.06 M Tris-HC1, pH 6.8,O. 15 M NaCl, then supplemented with 5% SDS, 10% glycerol, 0.02% bromophenol blue, heated at 60°C for 20 min, and finally submitted to 1 1 % homogenous gel SDS-PAGE in the absence of reducing agent [except in the case of the I4C-labeled reference proteins (Amersham, UK)]. Running conditions were constant voltage (60 V) for about 15 h, then constant current (30 mA/gel) until the marker dye exited. The proteins were then electroblotted onto a nitrocellulose sheet for 2 h under constant current (1 A). After quenching of the nitrocellulose at 4°C with Nonidet P 40 (Sigma Chemical Co., St. Louis, MO), BSA, and Tween 20 and 24 or 36 h of incubation with 200 000 cpm 1251-IGF-I or -11 at 4"C, the BP were detected by autoradiography. The specificity of the binding was checked by incuba- . . (Fig. 1, Table 1 ). Fetal IGF-I concentrations averaged 50 ng/mL up to 33 wk of pregnancy. Thereafter, they increased 2-to 3-fold at term. IGF-I1
. levels increased from approximately 350 ng/mL to twice that level at birth. Relationships between I G F and PL Levels. The regression curves for IGF-I and IGF-I1 versus PL levels are shown in Figure  2 . Covariance analysis was used to test correlations between PL, IGF-I, and IGF-11. Two periods were considered: that before and that after the 33rd wk of gestation. No correlation was found before wk 33, but after wk 33 there were significant ( p < 0.05) correlations between PL and both IGF-I and IGF-I1 levels. Covariance analysis also showed that the differences between the regression curves were significant ( p < 0.00 1).
Relafionships befween IGF Levels and Fefal Size. Normal fefuses (Fig. 3) . The fetuses were divided into two groups on the basis of growth: those with weights above the mean for gestational age (large) and those with weights below the mean (small).
When IGF values were plotted as a function of age, the regression curve for IGF-I in large fetuses was clearly above that in small fetuses, whereas the regression curves for IGF-I1 in the two groups were very close. Variance analysis showed that when all ages were included there was a significant difference between large and small fetuses ( p < 0.00 1) in IGF-I but not IGF-I1 levels.
Separate analysis of the data from early (before wk 33) and late (after wk 33) gestation revealed that for PL and IGF-I1 there were no significant differences in either category of gestational age between large and small fetuses. For IGF-I, by contrast, although there was no significant difference before wk 33, the difference after wk 33 was highly significant (p < 0.001). Intrauterine growth retardation (Fig. 4) . When IGF levels measured between wk 28 and 37 in 16 subjects with IUGR were plotted as a function of gestational age, IGF-I was below the mean for normal fetuses in 13 cases, whereas IGF-I1 fell on either side of the normal curve. Variance analysis showed that IGF-I levels were significantly lower than those in normal fetuses ( p < 0.01), but IGF-I1 levels were similar to normal.
Analysis of IGF BP. Binding activity measured in eight serum samples from 21-to 24-wk-old fetuses was 0.36 k 0.03 (SEM) U/mL, which is '/3 of that in adults (1.06 + 0.07 U/mL, n = 12).
With electrophoretic analysis of the BP (Fig. 5) , twice the amount of fetal serum was needed to obtain bands of similar intensity to children over the age of 3); 2) a consistently increased 34-kD form; and 3 ) a sometimes moderately, but generally markedly, increased 30-kD form. Close analysis revealed that in the fetus this form migrated slightly faster than the postnatal serum form, like the corresponding form found in amniotic fluid (~2 8 kD). The profiles shown in the figure are representative of all the sera tested. The changes in expression of the different BP seen in some samples were unrelated to fetal age. In newborns, the 30-kD material appeared as a doublet, the faster-moving, less abundant form migrating like the fetal form, and the slower-moving, more abundant form migrating like the postnatal form. Another feature peculiar to the fetus was the increased 24-kD form.
In the five cases of IUGR analyzed, the BP profiles resembled those of newborns more than those of fetuses of the same age, with more abundant 41.5-and 38.5-kD BP and a 30-kD BP appearing as a doublet.
Distribution oJthe IGF among the 150-kD and 40-kD IGF-BP Complexes. Figure 6 shows the relative proportions of IGF-I and IGF-I1 measured in the material containing either 150-kD or 40-kD IGF-BP complexes separated by neutral pH gel filtration.
In normal adults, approximately 75% of both IGF-I and IGF-I1 are found in the 150-kD and 25% are found in the 40-kD complexes. In newborns (cord blood), as in hypopituitary patients, the IGF are similarly distributed among the two types of complex, with a slight preference for the 40-kD complexes. DISCUSSION those obtained with adult samples. Qualitatively, the fetal profiles resembled those of patients with GH deficiency: 1 ) small Investigation of the changes in serum IGF-I and IGF-I1 levels amounts of the 41.5-and 38.5-kD BP, which increased slightly from the 20th wk of fetal life until birth yielded two major toward term (these BP are predominant in normal adults and findings. First, IGF-I1 levels were four to seven times those of IGF-I. The highest IGF-II/IGF-I ratios were seen between wk 20 and 22. In view of IGF-I and IGF-I1 levels in liver culture media (23) and of mRNA in tissue extracts (18) , these levels could reflect predominant IGF-I1 synthesis in human fetal liver.
Secondly, IGF-I and IGF-I1 levels rose during the last two mo of fetal life. In man, hepatic synthesis does not appear to switch from IGF-I1 toward IGF-I, as it does in the rat during the neonatal period when serum IGF-I1 levels crash (1). This may be because in man expression of the IGF-I1 gene in the fetal liver is controlled by two promoters (Pz and P,), whereas after birth it is controlled by another (PI) (3 1). Both IGF-I1 and IGF-I levels are lower in the fetus than in children and adolescents (results not shown) and in adults. They are of the same order of magnitude as those of patients with total GH deficiency. It is well known that the GH secreted by the fetal human hypophysis fails to influence the synthesis of IGF in the liver because of the immaturity of GH receptors (review in 32). However, the small amounts of PL passing into the fetal circulation are capable of interacting with its hepatic receptors whose specificity has now been demonstrated (33) . Analysis of our data showed that, after the 33rd wk of gestation, correlations exist between serum levels of both IGF-I and PL, and IGF-I1 and PL. This suggests that PL may have some regulatory role in IGF biosynthesis by human fetal liver, as has been shown in cultured fetal hepatocytes (34) . Also, Hill et al. (33) found the weight of the human fetus to correlate positively with PL-binding capacity of the liver and to a lesser extent with plasma PL concentrations. Furthermore, placental GH, whose levels in the maternal circulation are compatible with interaction with GH receptors, is not detectable in fetal blood (35) .
The role of the IGF in fetal statural growth and weight increase remains poorly understood. Years ago, some studies demonstrated correlations between IGF levels and either weight or size at birth (5) (6) (7) (8) . More recently, Ashton el al. (36) have found correlations between levels of IGF-I (but not of IGF-11) and fetal weight and length, as well as placental weight. In a study of fetal human chondrocytes in culture, IGF-I1 was reported to have a greater mitogenic capacity than IGF-I (1 3).
Our findings agree with those of Ashton et al. (36) in that we see a significant correlation between IGF-I levels and fetal weight, but no such relationship for IGF-11. However, we have found no relationship between IGF-I levels and birth length (results not shown). In the 16 subjects with IUGR, IGF-I levels were significantly lower than in normal fetuses of the same age, whereas IGF-I1 levels were similar. Our earlier findings that 19-to 24-wk-old hypotrophic fetuses have depressed serum growth-promoting activity (37) are relevant here, as is an earlier report showing low somatomedin activity in cord serum from infants with IUGR (38) . DeChiara et al. (39) have recently used homologous recombination to obtain heterozygous mice that cany an inactivated IGF-I1 gene and that as a result are growth deficient. It would appear that the mutation exerts its effect early, during the embryonic period. Our data suggest that IGF-I, but not IGF-11, is involved in the control of fetal size, at least during the final months of intrauterine life. This, however, does not exclude paracrine and/or autocrine action of IGF-I and IGF-I1 in the processes of cell growth and differentiation (19) . The electrophoretic profile of the IGF-binding proteins during fetal life strongly resembles that of patients with GH deficiency (29) . The 41.5-and 38.5-kD BP, which appear in small quantities in the fetus, represent the two molecular forms of the BP purified from serum (40) , whose cDNA has been cloned (41) and which is now known as IGFBP-3 (42). They bind IGF to form either binary complexes eluting in gel filtration around 40 kD, or, in association with a nonbinding subunit, ternary complexes of about 150 kD whose synthesis appears to be GH-dependent (2 1, 22). The 30-kD and especially the 34-kD forms are strongly expressed in the fetus and, after birth, seem to be negatively controlled by GH, inasmuch as they are increased in hypopituitarism and barely detectable in acromegaly (29) . The 30-kD form corresponds to a BP that has been purified from amniotic fluid (43, 44) and Hep G2 human hepatoma culture medium (43, whose cDNA has been cloned (46, 47) and which is named IGFBP-1 (42). The 34-kD BP characteristically predominates in cerebrospinal fluid and has a selective affinity for IGF-I1 (48) . The hepatic form has recently been cloned from a liver cDNA library and named IGFBP-2 (49). The 34-, 30-, and 24-kD BP associate with IGF to form only binary complexes (22) .
The circulating form of the IGF-II/mannose 6-phosphate receptor has been detected in monkey cord serum and found to be associated to approximately 20% IGF-I1 (50) . With the type of gel we use for the chromatographic separation of the 150-kD and 40-kD complexes in human cord serum, possible coelution of receptor with the 150-kD complexes cannot be excluded. Nevertheless, the relative proportions of IGF-I and IGF-I1 in pooled fractions containing both complexes were almost identical, with a slight preference for the 40-kD complexes. This resembles the picture in GH-deficient patients. In normal adults, 70 to 80% of the IGF are associated with the 41.5-and 38.5-kD BP in the form of 150-kD complexes. Our results differ from those of D'Ercole et al. (5 1 ) who found somatomedin-C/IGF-I eluting from gel filtration essentially around 40 kD in fetuses of 27 wk or less, but mostly with the 150-kD material in fetuses of 30 wk or more. Physiologically, it is important to remember that the binary 40-kD complexes are capable of crossing the capillary barrier, whereas the ternary 150-kD complexes are not (52) , which means that the circulating half-lives of the IGF depend on the relative proportions of these complexes (53) . Consequently, the situation in the fetus would favor transport of the IGF toward their target cells and, therefore, turnover. During fetal life, when IGF circulate at very low levels compared with those in adolescents and adults, BP synthesis would therefore be adapted to increase the bioavailability of the IGF at a time when growth is at maximum.
